Drugs / DALOSIRVAT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02503137 | Aug 2015 → Apr 2016 | androgenetic alopecia | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02275351 | Nov 2014 → Nov 2015 | androgenetic alopecia | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03742518 | Nov 2018 → Dec 2020 | androgenetic alopecia | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DALOSIRVAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650339 ↗ |
| Known as | SM04554 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02503137 ↗ |
| Modality | Small molecule | — CHEMBL4650339 ↗ |
| Route | Topical | “Topical solution, applied once a day” NCT02275351 ↗ |